Table 2.
Input Parameters of Quantitative Benefit-Risk Models Used for Rotavirus Vaccination
| Source | Location | Vaccine(s) | Vaccine Efficacy/Effectiveness | Vaccine Coverage | IS Risk Period (Days): Relative Risk | Birth Cohort | |||
|---|---|---|---|---|---|---|---|---|---|
| Patel et al [42] | LMIC (117) | Rotarix/RotaTeq | D1: 50% D2 and D3: 75% | 54% | D1 (1–7): 6.0 | NR | |||
| D2 (1–7): 3.0 | |||||||||
| D3 (1–7): 1.0 | |||||||||
| Patel et al [18] | Brazil | Rotarix | D1 and D2: 85% | 50% | Brazil | Mexico | 3 068 249 | ||
| D1 (1–7): | 1.1 [0.3–3.3] | 5.3 [3.0–9.3] | |||||||
| Mexico | Rotarix | D1 and D2: 85% | 50% | 2 414 329 | |||||
| D2 (1–7): | 2.6 [1.3–5.2] | 1.8 [0.9–3.8] | |||||||
| D1 (8–14): | 1.3 [0.5–3.4] | 1.1 [0.5–2.7] | |||||||
| D2 (8–14): | 1.4 [0.7–3.0] | 2.2 [1.1–4.2] | |||||||
| D1 (15–21): | 0.2 [0.0–1.4] | 0.9 [0.3–2.2] | |||||||
| D2 (15–21): | 0.9 [0.4–2.0] | 2.2 [1.2–4.0] | |||||||
| Desai et al [39] | Latin America (14) | Rotarix/RotaTeq | Hosp: 66% [31–83] to 85% [72–93] Death: 80% [59–90] to 100% [74–100] | 54%−92% | D1 (1–7): 5.3 [3.0–9.3] | 9 588 000 | |||
| D2 (1–7): 2.6 [1.3–5.2] | |||||||||
| Patel et al [43] | LMIC (158) | Rotarix/RotaTeq | 61% [44–73] to 97% [84–100] | Country-specific | D1 (1–7): 5.5 [4.1–7.5] | 123 600 000 | |||
| D2 (1–7): 1.7 [1.2–2.4] | |||||||||
| Carlin et al [17] | Australia | Rotarix/RotaTeq | D1: 50% D2 and D3: 80% | 85% | Rotarix | RotaTeq | 290 446 | ||
| D1 (1–7): | 6.8 [2.4–19.0] | 9.9 [3.7–26.4] | |||||||
| D1 (8–21): | 3.5 [1.3–8.9] | 6.3 [2.8–14.4] | |||||||
| D2 (1–7): | 2.8 [1.1–7.3] | 2.8 [1.2–6.8] | |||||||
| Desai et al [38] | United States | RotaTeq | D1: 66% [16–86] D2: 90% [75–96] D3: 92% [86–96] | D1: 96% D2: 93% D3: 82% | D1 (1–7): 5.3 [3.0–9.3] | 4 261 494 | |||
| Clark et al [37] | England | Rotarix | D1 >6 m: 96% [90.2–98.8] D1 >12 m: 90.7% [85.6–94.3] D2 >4 m: 100% [81.8–100] D2 >10 m: 92.2% [65.6–99.1] | D1 >15 w: 96% D2 >24 w: 94% | D1 (1–7): 6.8 [2.4–19.0] | 656 457 | |||
| D1 (8–21): 3.5 [1.3–8.9] | |||||||||
| D2 (1–7): 2.8 [1.1–7.3] | |||||||||
| D2 (8–21): 2.1 [1.0–4.6] | |||||||||
| Yung et al [44] | Singapore | Rotarix | D1: 50% D2: 80% | 90% | D1 (1–7): 8.4 [2.4–29.0] | 40 000 | |||
| D2 (1–7): 3.1 [0.4–23.4] | |||||||||
| D2 (8–21): 1.5 [0.2–11.7] | |||||||||
| Ledent et al [41] | Japan | Rotarix | D1: 73.9% [50.1–83.7] D2: 91.6% [62.4–99.1] | D1: 100% D2: 98% [95–98] | D1 (1–7): 5.4 [3.9–7.4] | 1 018 400 | |||
| D2 (1–7): 1.8 [1.2–2.7] | |||||||||
| Lamrani et al [40] | France | Rotarix/RotaTeq | RotarixD1 >6 m: 96% [90.2–98.8]D1 >12 m: 90.7% [85.6–94.3]D2 >4 m: 100% [81.8–100]D2 >10 m: 92.2% [65.6–99.1] | RotaTeqD1 <12 m: 58.9% [51.7–65.0]D1 >24 m: 53.6% [46.4–59.7]D2 <12 m: 77.4% [71.1–82.1]D2 >24 m: 72.1% [65.8–76.8]D3 <12 m: 95.8% [90.5–98.2]D3 >24 m: 88.0% [82.7–90.4] | D1: 92% D2: 88% D3: 84% | Rotarix | RotaTeq | 765 550 | |
| D1 (1–7): | 6.8 [2.4–19.0] | 9.9 [3.7–26.4] | |||||||
| D1 (8–21): | 3.5 [1.3–8.9] | 6.3 [2.8–14.4] | |||||||
| D2 (1–7): | 2.8 [1.1–7.3] | 2.8 [1.2–6.8] | |||||||
| D2 (8–21): | 2.1 [1.0–4.6] | 1.8 [0.8–3.9] | |||||||
| Ledent et al [48] | France | Rotarix | D1: 75% [55–88] D2: 90% [81–95] | D1: 100% D2: 92% [72–100] | D1 (1–7): 5.4 [3.9–7.4] | 791 183 | |||
| D2 (1–7): 1.8 [1.3–2,5] | |||||||||
| Bruijning-Verhagen et al [45] | Netherlands | RotaTeq | D1 and D2: 88% D3: 94.8% | 86% | NR | 171 387 | |||
| Bruun et al [46] | Norway | Rotarix | D1 and D2: 93% [87–98] | D1: 91% D2: 86% | D1 (1–21): 2.4 [1.5–3.8] | 60 000 | |||
| D2 (1–21): 1.8 [1.3–2.4] | |||||||||
| Clark et al [47] | LMIC (135) | Rotarix/RotaTeq/ ROTAVAC/ROTASIIL/ RV3-BB | 79% [75–82] to 100% [99–100] | Country-specific | D1 (1–7): 6.3 [4.3–9.2] | 60 000 000 | |||
| D1 (8–21): 1.7 [1.1–2.7] | |||||||||
| D2 (1–7): 1.8 [1.4–2.3] | |||||||||
| D2 (8–21): 1.4 [1.0–1.8] |
Abbreviations: D1, dose 1; D2, dose 2; D3, dose 3; Hosp, hospitalization; IS, intussusception; LMICs, low- and middle-income countries; m, months; N, number; NR, not reported; w, weeks.